Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07232875 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Name: HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer — clinical trial record (NCT07232875)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorJiangsu HengRui Medicine Co., Ltd.

Started2025-11-21

View on ClinicalTrials.gov ↗

Amendment history

2026-07-14

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-12→confirmed 2025-11-21

Study sitesdetails revised at 1 of 1 site

2025-11-14

Original filing

Jiangsu HengRui Medicine Co., Ltd.

126 trials monitored

See 6 trials at risk

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.

Trial Details

NCT Number	NCT07232875
Lead Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions	KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Enrollment	588 participants
Start Date	2025-11-21
Primary Completion	2029-04 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-15